This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2008 Oct;23(10):3053-5.

doi: 10.1093/ndt/gfn326. Epub 2008 Jun 16.

The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia

Shaun Summers, Stephen Holdsworth, Edward Sharples

PMID: 18558625
DOI: 10.1093/ndt/gfn326

Review

The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia

Shaun Summers et al. Nephrol Dial Transplant. 2008 Oct.

. 2008 Oct;23(10):3053-5.

doi: 10.1093/ndt/gfn326. Epub 2008 Jun 16.

Authors

Shaun Summers, Stephen Holdsworth, Edward Sharples

PMID: 18558625
DOI: 10.1093/ndt/gfn326

No abstract available

PubMed Disclaimer

Comment on

Update on reintroduction of epoetin in a patient with pure red call aplasia.
Campbell N, Krishnakumar S, Matijevic A, Almond M. Campbell N, et al. Nephrol Dial Transplant. 2008 Oct;23(10):3365. doi: 10.1093/ndt/gfn328. Epub 2008 Jun 20. Nephrol Dial Transplant. 2008. PMID: 18567693 No abstract available.

Similar articles

[Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].
Rossert J, Casadevall N. Rossert J, et al. Nephrol Ther. 2006 Sep;2 Suppl 4:S283-6. Nephrol Ther. 2006. PMID: 17373271 French.
Pure red cell aplasia induced by erythropoiesis-stimulating agents.
Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pollock C, et al. Clin J Am Soc Nephrol. 2008 Jan;3(1):193-9. doi: 10.2215/CJN.02440607. Clin J Am Soc Nephrol. 2008. PMID: 18178785 Review.
Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation.
Praditpornsilpa K, Buranasot S, Bhokaisuwan N, Avihingsanon Y, Pisitkul T, Kansanabuch T, Eiam-Ong S, Chusil S, Intarakumtornchai T, Tungsanga K. Praditpornsilpa K, et al. Nephrol Dial Transplant. 2005 Mar;20(3):626-30. doi: 10.1093/ndt/gfh666. Nephrol Dial Transplant. 2005. PMID: 15735244 No abstract available.
Erythropoietin and renal failure.
Macdougall IC. Macdougall IC. Curr Hematol Rep. 2003 Nov;2(6):459-64. Curr Hematol Rep. 2003. PMID: 14561389 Review.
Prolonged course of pure red cell aplasia after erythropoietin therapy.
Nigg L, Schanz U, Ambühl PM, Fehr J, Bachli EB. Nigg L, et al. Eur J Haematol. 2004 Nov;73(5):376-9. doi: 10.1111/j.1600-0609.2004.00317.x. Eur J Haematol. 2004. PMID: 15458518

See all similar articles

Cited by

Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.
Lee H, Yang J, Kim H, Kwon JW, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, Kim S. Lee H, et al. J Korean Med Sci. 2010 Nov;25(11):1676-9. doi: 10.3346/jkms.2010.25.11.1676. Epub 2010 Oct 26. J Korean Med Sci. 2010. PMID: 21060762 Free PMC article.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems